Challenges in management of warfarin anti-coagulation in advanced HIV/aids patients with venous thrombotic events – a case series from a research clinic in rural Kericho, Kenya

East African Medical Journal

Volumn 90, Issue 7, 2013, Pages 207-213

  Tarus, N K ^a   Pau, A K ^b   Sereti, I ^b   Kirui, F K ^a   Sawe, F K ^a   Agan, B K ^c   Momanyi, L M ^d   Ngeno, H C ^a   Koskei, G K ^a   Shaffer, D N ^a  

^a KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^d Catholic Relief Services   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

ADULT; CD4 LYMPHOCYTE COUNT; COMPLICATION; DISEASE MANAGEMENT; DOPPLER ECHOGRAPHY; DRUG INTERACTION; DRUG MONITORING; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN; INTERNATIONAL NORMALIZED RATIO; KENYA; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PATIENT ACUITY; PATIENT CARE; PROCEDURES; RURAL POPULATION; STATISTICS AND NUMERICAL DATA; VENOUS THROMBOSIS;

ADULT; ANTICOAGULANTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DISEASE MANAGEMENT; DRUG INTERACTIONS; DRUG MONITORING; FEMALE; HIV INFECTIONS; HUMANS; INTERNATIONAL NORMALIZED RATIO; KENYA; MALE; MIDDLE AGED; PATIENT ACUITY; PATIENT CARE TEAM; RURAL POPULATION; ULTRASONOGRAPHY, DOPPLER, DUPLEX; VENOUS THROMBOSIS; WARFARIN;

EID: 84964696348     PISSN: 0012835X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Fultz SL, McGinnis KA, Skanderson M, et al. Association of venous thromboembolism with human immunodeficiency virus and mortality in veterans. AM J Med. 2004; 116:420-423.
2. Copur AS, Smith PR, Gomez V, et al. HIV infection is a risk factor for venous thromboembolism. AIDS Patient Care STDS. 2002; 16:205-209.
3. Katie LK, Melissa EB. Risk factors for venous thromboembolism in patients with human immunodeficiency virus infection. Pharmacotherapy. 2010; 30:1292-1302.
4. Crum-Cianflone NF, Weekes J, Bavaro M. Review: Thromboses among HIV-Infected Patients during the Highly Active Antiretroviral Therapy Era. AIDS Patient Care and STDS. 2008; 22:771-778.
5. Musselwhite LW, Sheikh V, Norton TD et al. Markers of endothelial dysfunction, coagulation and tissue fibrosis independently predict venous thromboembolism in HIV. AIDS. 2011; 25: 787-95.
6. Saif MW, Greenberg B. HIV and Thrombosis: A review. AIDS Patient Care and STDS. 2001;15(1):15-24
7. Hirsh J, Lee AYY. How we diagnose and treat deep vein thrombosis. Blood. 2002; 9:3102-3110.
8. Fihn SD, McDonnell M, Martin D et al. Risk factors for complications of chronic anti-coagulation: A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group. Ann Intern Med. 1993; 118:511-520.
9. Hamby L, Weeks WB, Malikowski C. Complications of warfarin therapy: Causes, costs, and the role of anti-coagulation clinic. Eff Clin Pract 2000;3:179-84
10. Holbrook AM, Pereira JA, Labiris R, et al. Systemic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005; 165:1095-1106.
11. Goldstein KM, Gluckman S, Mounzer K. Challenge of coadministering antiretroviral therapy and oral anti-coagulants in HIV-positive patients. AIDS Read. 2008; 18: 480-2, 486-9.
12. LiverpoolHIVPharmacologyGroup. Druginteractions charts. http://www.hiv-druginteractions.org/ frames.asp?drg. Accessed Jan 2012.
13. Dioniso D, Mininni S, Bartolozzi D, et al. Need for increased dose of warfarin in HIV patients taking nevirapine. AIDS. 2001;15:277-278
14. Liedtke MD, Rathbun RC. Warfarin –antiretroviral interactions. Ann Pharmacother. 2009;43:322-8
15. Hughes CA, Freitas A, Miedzinski LJ. Interaction between lopinovir/ritonavir and warfarin. CMAJ. 2007; 177:357-359.
16. Yeh RF, Gaver VE, Patterson KB, et al. Lopinavir/ ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9,CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping cocktail in healthy volunteer. J Acquir Immune Defic Syndr. 2006; 42:52-60.
17. Lee CR, Thrasher KA. Difficulties in anti-coagulation management during coadministration of warfarin and rifampin. Pharmacotherapy 2001; 21: 1240-6.
18. Fischer HD, Juurlink DN, Mamdani MM, Kopp A, Laupacis A. Hemorrhage during warfarin therapy associated with cotrimoxazole and other urinary tract anti-infective agents: A population-based study. Arch Intern Med. 2010; 170: 617-21.
19. Immune Reconstitution Syndrome in HIV-Infected Patients Taking Antiretroviral Therapy(NCT00286767) in Clinical Trials.gov
20. National AIDS and STI Control Programme, Ministry of Health, Kenya. Kenya National Clinical Manual for ART providers: A concise and Practical Guide to ART Provision. 4th Edition. Nairobi, Kenya: NASCOP; 2011.
21. Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach-2010 version. Geneva: World Health Organization, 2010.
22. National AIDS and STI Control Programme (NASCOP), Ministry of Health, National Manual for the Management of HIV-Related Opportunistic Infections and Related Conditions. 2008, BALTECH EQUIPMENTS LTD.
23. Ministry of Health, Government of Kenya. Available from: Http://www.statehousekenya.go.ke/ government/health.htm. Accessed Jan 2012
24. The Kenya Medical Research Institute (KEMRI). Available from: Http://www.kemri.org. Accessed Jan 2012
25. U.S. Military HIV Research Program (MHRP). Available from: Http://www.hivresearch.org/home. php. Accessed Jan 2012
26. The United States President’s Emergency Plan for AIDS Relief. Available from: Http://www.pepfar. gov/ accessed Jan 2012
27. Buller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: The seventh AACP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126:401-428
28. Greenblatt DJ, Von Moltke LL. Interaction of warfarin with drugs, natural substances and foods. J Clin Pharmacol.2005;45:127-32.
29. Buller HR, Prins MH, Lensing AWA, et al. Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism. N Engl J Med. 2012
30. Manji I, Pastakia SD, DO AN, et al. Performance outcomes of a pharmacist-managed anti-coagulation clinic in rural, resource-constrained setting of Eldoret, Kenya. J Thromb Haemost. 2011;9:2215-20